The as-yet unfulfilled promise of p38 MAPK inhibitors.
Sweeney
Susan E
SE
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000201:enzymology; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D007527:Isoenzymes; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
D018501:Antirheumatic Agents; D007527:Isoenzymes; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; C517771:VX 702; D048051:p38 Mitogen-Activated Protein Kinases